公开(公告)号：US20160022792A1

公开(公告)日：2016-01-28

申请号：US14819909

申请日：2015-08-06

Applicant: Baylor Research Institute

Inventor： Gerard Zurawski ,  Jacques F. Banchereau ,  Anne-Laure Flamar ,  Peter Klucar ,  Keiko Akagawa ,  Sandra Zurawski ,  SangKon Oh

IPC: A61K39/00 ,  C07K14/435 ,  C07K16/28

CPC classification number: A61K39/0011 ,  A61K2039/6056 ,  C07K14/435 ,  C07K16/2878 ,  C07K2319/00 ,  C07K2319/33 ,  C07K2319/91 ,  Y02A50/39 ,  Y02A50/466

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

Abstract translation: 本发明包括用于表达，分泌和使用用作例如疫苗和抗原递送载体的用于将抗原递送至抗原呈递细胞的组合物和方法。 在一个实施方案中，载体是抗CD40抗体或其片段，以及与抗-CD40抗体或其片段（包括人源化抗体）连接的一个或多个抗原肽。

公开(公告)号：US20150133469A1

公开(公告)日：2015-05-14

申请号：US14384891

申请日：2013-03-13

Applicant: BAYLOR RESEARCH INSTITUTE ,  MEDICAL RESEARCH COUNCIL ,  IMPERIAL COLLEGE HEATHCARE NHS TRUST

Inventor： Anne O'Garra ,  Chloe Bloom ,  Matthew Paul Reddoch Berry ,  Robert Wilkinson ,  Jacques F. Banchereau ,  Damien Chaussabel ,  Maria Virginia Pascual

IPC: C12Q1/68 ,  A61K31/133 ,  A61K31/455 ,  A61K31/496 ,  A61K31/4965

CPC classification number: C12Q1/6883 ,  A61K31/133 ,  A61K31/455 ,  A61K31/496 ,  A61K31/4965 ,  C12Q1/68 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/48 ,  G01N33/68 ,  G01N33/6893 ,  G01N2333/35 ,  G01N2800/26 ,  G01N2800/52

Abstract: The present invention includes methods for early detection of a treatment response in a patient suspected of being infected with Mycobacterium tuberculosis. Changes in the blood transcriptome are detectable within two weeks of the initiation of antituberculosis therapy.

Abstract translation: 本发明包括在怀疑感染结核分枝杆菌的患者中早期检测治疗反应的方法。 在抗结核治疗开始后两周内，血液转录组的变化是可检测的。

公开(公告)号：US20140288175A1

公开(公告)日：2014-09-25

申请号：US14214317

申请日：2014-03-14

Applicant: Baylor Research Institute

Inventor： Charles R. ROE

IPC: A61K31/225 ,  A61K31/19 ,  A61K31/22

CPC classification number: A61K31/225 ,  A23K20/158 ,  A23K20/174 ,  A23K50/10 ,  A23K50/75 ,  A23K50/80 ,  A23L2/52 ,  A23L33/10 ,  A23L33/115 ,  A23L33/12 ,  A23L33/16 ,  A23L33/175 ,  A23V2002/00 ,  A61K9/0053 ,  A61K9/0095 ,  A61K31/19 ,  A61K31/20 ,  A61K31/202 ,  A61K31/22 ,  A61K31/23 ,  A61K38/47 ,  C12Y302/0102

Abstract: A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.

Abstract translation: 通过施用有效量的包含能够改善这些疾病的症状的生酮类奇碳脂肪酸的组合物来治疗糖原贮积病的方法。

公开(公告)号：US20140221482A1

公开(公告)日：2014-08-07

申请号：US14106078

申请日：2013-12-13

Applicant: Baylor Research Institute at Dallas ,  National Institute of Health and Medical Research

Inventor： Fanny Mochel ,  Raphael Schiffmann

IPC: A61K31/23 ,  A23L1/30

CPC classification number: A61K31/225 ,  A23L33/12 ,  A23V2002/00 ,  A61B6/037 ,  A61B6/501 ,  A61K9/0053 ,  A61K9/48 ,  A61K31/23 ,  A61K45/06 ,  G01N33/64 ,  A61K2300/00

Abstract: Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.

Abstract translation: 提供了治疗GLUT1和相关脑能量缺乏的方法，其包括施用奇 - 碳脂肪酸来源，例如C5或C7脂肪酸来源以及相关组合物。

公开(公告)号：US20140199763A1

公开(公告)日：2014-07-17

申请号：US14152448

申请日：2014-01-10

Applicant: Institut National de la Sante et de la Recherche Medicale ( INSERM) ,  Baylor Research Institute

Inventor： Helene Dutartre ,  Yves Levy ,  Jacques Banchereau ,  Gerard Zurawski

IPC: C12N5/0784

CPC classification number: C12N5/0639 ,  A61K39/12 ,  A61K39/29 ,  A61K2039/6056 ,  C07K14/005 ,  C07K16/2851 ,  C07K16/2878 ,  C07K2319/00 ,  C07K2319/33 ,  C12N2770/24222 ,  C12N2770/24234

Abstract: Compositions comprising viral antigens and antigenic peptides corresponding to or derived from Hepatitis C virus (HCV) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs) are described herein. Included herein are immunostimulatory compositions (HCV vaccines, HCV antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C.

Abstract translation: 本文描述了包含与针对树突状细胞（DC）特异性的抗体的重链和/或轻链或其片段融合的丙型肝炎病毒（HCV）蛋白或其片段的病毒抗原和抗原肽的组合物。 本文包括免疫刺激组合物（HCV疫苗，呈递树突细胞的HCV抗原等）以及用于增加抗原呈递细胞的HCV抗原呈递的有效性的方法，用于治疗，预防或其组合以抗人类受试者中的丙型肝炎 ，以及通过激活一种或多种树突状细胞提供免疫刺激的方法，治疗或预防丙型肝炎的方法。

公开(公告)号：US20130197084A1

公开(公告)日：2013-08-01

申请号：US13794493

申请日：2013-03-11

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Charles R. Roe

IPC: A61K31/20

CPC classification number: A61K31/20 ,  A61K31/19 ,  A61K31/22 ,  A61K31/23

Abstract: The present invention includes compositions and methods for treating the effects of catabolism in a patient by providing the patient with an amount of an odd-chain fatty acid sufficient to increase the intracellular ratio of AMP to ATP and reduce the activity of AMPK.

Abstract translation: 本发明包括通过向患者提供足以增加AMP与ATP的细胞内比例并降低AMPK活性的奇数链脂肪酸的量来治疗患者分解代谢作用的组合物和方法。

公开(公告)号：US20250144191A1

公开(公告)日：2025-05-08

申请号：US19010936

申请日：2025-01-06

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Gerard ZURAWSKI

IPC: A61K39/00 ,  A61P25/00 ,  A61P25/28 ,  A61P37/02 ,  C07K14/46 ,  C07K16/28

Abstract: Methods and compositions for treating multiple sclerosis using dendritic cell anti-ASGPR antibodies fused to myelin basic protein or myelin oligodendrocyte glycoprotein are provided.

公开(公告)号：US12214034B2

公开(公告)日：2025-02-04

申请号：US18329696

申请日：2023-06-06

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Sangkon Oh ,  Sandra Zurawski ,  Gerard Zurawski

IPC: A61K39/12 ,  A61K39/395 ,  C07K14/005 ,  C07K14/025 ,  C07K16/28 ,  C12N7/00 ,  A61K39/00

Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

公开(公告)号：US20240033340A1

公开(公告)日：2024-02-01

申请号：US18329696

申请日：2023-06-06

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Sandra ZURAWSKI ,  Gerard ZURAWSKI

IPC: A61K39/12 ,  A61K39/395 ,  C07K16/28 ,  C07K14/005 ,  C12N7/00

CPC classification number: A61K39/12 ,  A61K39/395 ,  A61K39/39541 ,  C07K16/2878 ,  A61K39/3955 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/20034 ,  A61K2039/505

Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

公开(公告)号：US20230183366A1

公开(公告)日：2023-06-15

申请号：US17998611

申请日：2021-05-11

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCH MÉDICALE) ,  UNIVERSITE PARIS EST CRETEIL VAL DE MARNE ,  BAYLOR RESEARCH INSTITUTE ,  ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

Inventor： Yves LEVY ,  Sandra ZURAWSKI ,  Gérard ZURAWSKI

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61P35/00 ,  C07K2317/565

Abstract: The disclosure relates to the field of OX40 activating proteins. More specifically, it is disclosed herein recombinant proteins with OX40 agonist antibodies or their antigen-binding fragments fused or linked to OX40 ligand. Also disclosed is the advantageous use of such OX40 activating proteins, in particular for inducing immune responses directed to delivered antigens such as viral or cancer antigens, and/or for treating cancer.